2024 Comprehensive Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Management of Sjögren's Syndrome

IF 2.4 4区医学 Q2 RHEUMATOLOGY

International Journal of Rheumatic Diseases Pub Date : 2025-05-16 DOI:10.1111/1756-185X.70272

Galymzhan Togizbayev, Bakyt Aubakirova, Dina Dilmanova, Lina Zaripova, Aida Tabenova, Karlygash Karina, Larisa Makalkina

{"title":"2024 Comprehensive Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Management of Sjögren's Syndrome","authors":"Galymzhan Togizbayev, Bakyt Aubakirova, Dina Dilmanova, Lina Zaripova, Aida Tabenova, Karlygash Karina, Larisa Makalkina","doi":"10.1111/1756-185X.70272","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sjögren's syndrome (SjS) is a chronic autoimmune disease characterized by exocrine gland dysfunction and systemic involvement. Although international guidelines exist, regional adaptations are necessary to address specific healthcare settings. In 2024, the Qazaq College of Rheumatology (QCR) developed comprehensive national recommendations for the diagnosis and management of SjS in Kazakhstan.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A panel of national experts reviewed and synthesized international guidelines (EULAR, ACR, and BSR) alongside local clinical data to create tailored diagnostic and therapeutic algorithms. Special emphasis was placed on the management of severe systemic manifestations and accessibility of therapies within Kazakhstan's healthcare system.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The QCR recommendations propose a structured diagnostic approach combining clinical features, serological markers, and minor salivary gland biopsy. Treatment strategies emphasize non-pharmacological measures, symptomatic therapies, and immunomodulatory agents for systemic disease. Rituximab is prioritized as the first-line biologic for refractory severe extraglandular manifestations. A national registry for SjS is proposed to monitor implementation and outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These guidelines aim to standardize the diagnosis and management of Sjögren's syndrome across Kazakhstan, improve patient outcomes, and support further research initiatives.</p>\n </section>\n </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70272","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Sjögren's syndrome (SjS) is a chronic autoimmune disease characterized by exocrine gland dysfunction and systemic involvement. Although international guidelines exist, regional adaptations are necessary to address specific healthcare settings. In 2024, the Qazaq College of Rheumatology (QCR) developed comprehensive national recommendations for the diagnosis and management of SjS in Kazakhstan.

Methods

A panel of national experts reviewed and synthesized international guidelines (EULAR, ACR, and BSR) alongside local clinical data to create tailored diagnostic and therapeutic algorithms. Special emphasis was placed on the management of severe systemic manifestations and accessibility of therapies within Kazakhstan's healthcare system.

Results

The QCR recommendations propose a structured diagnostic approach combining clinical features, serological markers, and minor salivary gland biopsy. Treatment strategies emphasize non-pharmacological measures, symptomatic therapies, and immunomodulatory agents for systemic disease. Rituximab is prioritized as the first-line biologic for refractory severe extraglandular manifestations. A national registry for SjS is proposed to monitor implementation and outcomes.

Conclusion

These guidelines aim to standardize the diagnosis and management of Sjögren's syndrome across Kazakhstan, improve patient outcomes, and support further research initiatives.

查看原文本刊更多论文

2024年卡扎克风湿病学院关于Sjögren综合征诊断和管理的综合建议

背景Sjögren综合征（SjS）是一种以外分泌腺功能障碍和全身受累为特征的慢性自身免疫性疾病。尽管存在国际准则，但有必要根据具体的卫生保健环境进行区域调整。2024年，Qazaq风湿病学院（QCR）为哈萨克斯坦SjS的诊断和管理制定了全面的国家建议。方法由国家专家组成的小组审查并综合了国际指南（EULAR、ACR和BSR）以及当地临床数据，以创建量身定制的诊断和治疗算法。特别强调在哈萨克斯坦的医疗保健系统内对严重系统性表现的管理和治疗的可及性。结果：QCR推荐了一种结合临床特征、血清学标志物和小唾液腺活检的结构化诊断方法。治疗策略强调对全身性疾病的非药物措施、对症治疗和免疫调节剂。利妥昔单抗是治疗难治性严重腺外症状的首选一线生物药物。建议建立一个全国性的SjS登记处，以监测实施情况和结果。结论该指南旨在规范哈萨克斯坦Sjögren综合征的诊断和管理，改善患者预后，并支持进一步的研究计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Rheumatic Diseases RHEUMATOLOGY-

CiteScore

3.70

自引率

4.00%

发文量

362

审稿时长

1 months

期刊介绍： The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.